Hero Image

Business development and licensing (BD&L)

We’re focused on identifying breakthrough science and collaborating together to make the greatest difference for patients, now and in the future.

Collaborate with us


Partner with us

With a robust pipeline and portfolio fueled by both our own discoveries and external innovation, we know that collaborations are critical to advancing bold science. We share your urgency to transform health care for patients and will act decisively when there’s an opportunity to make a meaningful impact on patients’ lives. We leverage our company’s strengths, including our global capabilities from discovery research through commercialization, to work with our partners to bring new and life-changing therapies to patients.

Areas of research | R&D locations | Meet our team | BD&L news I Careers

Searching the world for cutting-edge science regardless of therapeutic area or modality

woman scientist using gloves

Our areas of focus

Merck building exterior

R&D locations

We’re open to collaboration anywhere the science leads us. Our teams are co-located within our research & development sites in Boston, South San Francisco and London — epicenters of scientific innovation.

Learn more about our team

"Our strength is our ability to translate science and develop compounds at scale. We will not be complacent in our pursuit of breakthrough science because patients are waiting.”

  • Sunil Patel
    Senior vice president, head of corporate development and BD&L
    Read his bio

We're active in dealmaking worldwide

We're unafraid to make bold investments in external science where we believe we can save and improve lives. See list of select deals.

BD&L news

Recent acquisitions and collaborations

With the acquisition of Prometheus Biosciences, we hope to usher in a new era of care for immune disorders based on a precision medicine.

Following our acquisition of Caraway Therapeutics, we’re evaluating novel mechanisms of action of lysosomal function in an effort to advance disease-modifying therapies for progressive neurodegenerative diseases.

Harpoon logo

As part of our acquisition of Harpoon Therapeutics, we’re investigating a novel class of T cell engagers designed to harness the power of the body’s immune system and help patients suffering from certain types of cancer and other diseases.

Venture funds

MRL Ventures Fund

The MRL Ventures Fund (MRLV) team invests globally in early-stage, preclinical therapeutics companies focused on delivering innovative therapies to improve patient care. Learn more.

Global Health Innovation

Merck Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. Learn more.